Cleveland BioLabs, Inc. (NASDAQ:CBLI) has released results for the last fiscal year, reporting EPS of $-0.33. For this year, EPS is expected to grow 86.50% over the previous year.
The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend. The market is approaching overbought territory. Be watchful of a trend reversal.
Recently, Cleveland BioLabs, Inc. (NASDAQ:CBLI) reported financial results and development progress for the first quarter ended March 31, 2017.
For the last five years, EPS at Cleveland BioLabs, Inc. has increased 37.10%, while rise sales have increased -16.70%% over the same period. Tthe combined EPS growth for the next five years is expected to be -%.
Shares of Cleveland BioLabs, Inc. are now trading at $4.14, giving it market capitalization of $45.62M. Over the last 12 months, shares of Cleveland BioLabs, Inc. have risen to maximum of $-25.41% and dropped to a minimum of $239.34%.
The stock?s beta, which is a measure of volatility, is 0.38. For the sake of clarifty, keep in mind that a bet of less than 1 indicates that a stock is less volatile compared to the overall market, while a beta greater than 1 implies a stock is more volatile than the market.
Cleveland BioLabs, Inc. has 20-Day Simple Moving Average of $23.25% and 50-Day Simple Moving Average of $58.60%. The 200-Day Simple Moving Average is $114.03%.
The stock’s weekly performance stands at 21.05%% while its monthly performance is 5.07%. Year-to-date the stock has moved 191.54% compared to a performance of 100.00%% over the last 12 months.
Cleveland BioLabs, Inc. has witnessed 0.00% insider transactions, leading to insider ownership of 3.83%. That compares to 2.40% ownership by institutional investors following -7.03% institutional transactions.
Return on investments in Cleveland BioLabs, Inc. for the trailing 12 months is -84.70%, while return on assets for the same period is -22.50%. Return on equity for the trailing 12 months, on the other hand, is -48.50%.
Cleveland BioLabs, Inc. has RSI (Relative Strength Index) of 64.98.